5.245 Unternehmen passen
Showing 3.651–3.700 of 5.245
| Unternehmen | Note | Kurs | Unter Hoch | KGV | Größe | Rendite | Optionen | Branche |
|---|---|---|---|---|---|---|---|---|
| C | 4,78 $ | -11 % | — | 159,4M $ | — | — | Software Infrastructure | |
| Ohne Note | 72,88 $ | -30 % | — | 159,2M $ | — | Monatlich | — | |
| Ohne Note | 23,15 $ | -76 % | — | 159,2M $ | — | Monatlich | Biotechnology | |
| Ohne Note | 5,51 $ | -14 % | — | 158,9M $ | — | — | — | |
| D | 8,16 $ | -97 % | — | 158,9M $ | — | — | Biotechnology | |
| F | 4,10 $ | -78 % | — | 158,9M $ | — | Monatlich | Electrical Equipment and Parts | |
| D- | 1,03 $ | -98 % | — | 158,8M $ | — | — | Information Technology Services | |
| Ohne Note | 10,11 $ | -1 % | — | 158,4M $ | — | — | Shell Companies | |
| B | 7,20 $ | -18 % | 8,28 | 158,3M $ | 41,9 % | Monatlich | Reit Mortgage | |
| C- | 3,08 $ | -69 % | — | 158,3M $ | — | Monatlich | Software Infrastructure | |
| Ohne Note | 5,97 $ | -60 % | 2,09 | 158M $ | — | Monatlich | Asset Management | |
| F | 5,02 $ | -66 % | — | 158M $ | — | Monatlich | Software Application | |
| Ohne Note | 2,15 $ | -66 % | — | 157,7M $ | — | — | Building Products and Equipment | |
| D- | 2,02 $ | -46 % | — | 157,3M $ | — | Monatlich | Health Information Services | |
| Ohne Note | 10,04 $ | 0 % | — | 157,2M $ | — | — | Shell Companies | |
| D- | 14,70 $ | -17 % | — | 157,1M $ | 3,1 % | Monatlich | Furnishings Fixtures and Appliances | |
| F | 3,26 $ | -15 % | — | 156,9M $ | — | Monatlich | Conglomerates | |
| C- | 2,95 $ | -49 % | — | 156,7M $ | 16,3 % | Monatlich | — | |
| C | 11,77 $ | -35 % | — | 156,3M $ | — | — | Oil Gas E and P | |
| D | 56,01 $ | -43 % | — | 156M $ | — | — | Biotechnology | |
| F | 3,38 $ | -73 % | — | 155,5M $ | — | Monatlich | Software Application | |
| Ohne Note | 2,53 $ | -67 % | — | 155,5M $ | — | Monatlich | Biotechnology | |
| Ohne Note | 0,73 $ | -66 % | — | 155,4M $ | — | — | Gold | |
| B- | 3,29 $ | -48 % | — | 155,4M $ | — | Monatlich | Medical Distribution | |
| F- | 1,28 $ | -59 % | — | 155M $ | — | Monatlich | Biotechnology | |
| C- | 0,55 $ | -63 % | — | 154M $ | — | Monatlich | Biotechnology | |
| C | 3,70 $ | -31 % | — | 153,9M $ | — | Monatlich | Biotechnology | |
| D | 22,00 $ | -21 % | 15,71 | 153,6M $ | 1,8 % | — | Banks Regional | |
| F+ | 8,45 $ | -66 % | 2,24 | 153,4M $ | — | — | Electronic Gaming and Multimedia | |
| D- | 1,20 $ | -30 % | — | 153M $ | — | — | Electronic Gaming and Multimedia | |
| B- | 0,45 $ | -86 % | — | 152,9M $ | — | Wöchentlich | Mortgage Finance | |
| D- | 3,38 $ | -84 % | — | 152,5M $ | — | Wöchentlich | Software Infrastructure | |
| C- | 7,36 $ | -40 % | — | 151,9M $ | — | Monatlich | Metal Fabrication | |
| Ohne Note | 14,28 $ | -47 % | — | 151,4M $ | — | — | — | |
| C | 21,26 $ | -17 % | 10,85 | 151,3M $ | 1,9 % | — | Banks Regional | |
| F- | 2,76 $ | -92 % | — | 151,3M $ | — | Monatlich | Biotechnology | |
| D- | 4,79 $ | -64 % | — | 151,2M $ | — | Monatlich | Aerospace and Defense | |
| B | 19,01 $ | -6 % | 37,27 | 150,8M $ | 1,2 % | — | Banks Regional | |
| Ohne Note | 3,33 $ | -93 % | — | 150,6M $ | — | Monatlich | Biotechnology | |
| C- | 0,72 $ | -96 % | — | 150,6M $ | — | Wöchentlich | Oil Gas Drilling | |
| Ohne Note | 4,79 $ | -57 % | — | 150,2M $ | — | — | Biotechnology | |
| B- | 1,28 $ | -53 % | 42,67 | 150,1M $ | — | Monatlich | Apparel Manufacturing | |
| D | 1,65 $ | -42 % | 2,50 | 150,1M $ | — | Monatlich | Real Estate Services | |
| F- | 1,46 $ | -59 % | — | 149,9M $ | — | Monatlich | Semiconductors | |
| Ohne Note | 1,88 $ | -69 % | — | 149,7M $ | — | Monatlich | Biotechnology | |
| D | 2,42 $ | -68 % | — | 149,3M $ | — | — | Medical Devices | |
| B | 18,44 $ | -3 % | 614,50 | 149,3M $ | — | — | Banks Regional | |
| D- | 2,61 $ | -12 % | — | 148,6M $ | 3,1 % | Monatlich | Reit Office | |
| Ohne Note | 10,11 $ | -0 % | — | 148M $ | — | — | Shell Companies | |
| C- | 1,40 $ | -43 % | — | 147,5M $ | — | Monatlich | Biotechnology |
Ein Filter ist keine Empfehlung. Jede Zeile hat die genannte Bedingung erfüllt und sonst nichts — InspectStocks beschreibt Unternehmen anhand ihrer eigenen SEC-Einreichungen und rät weder zum Kauf noch zum Verkauf.